Krystal Biotech's VYJUVEK Gene Therapy Approved by UK MHRA for Dystrophic Epidermolysis Bullosa
KRYS has more than doubled off its 52-week low of $122.8.
Summary
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Krystal Biotech's Beremagene Geperpavec (VYJUVEK) for the treatment of Dystrophic Epidermolysis Bullosa (DEB). This significant regulatory milestone expands the commercial reach of Krystal Biotech's lead gene therapy into a major international market. The approval follows the company's robust Q1 2026 financial results, which highlighted strong VYJUVEK sales as a key growth driver, indicating successful commercialization in other regions. This UK approval is expected to further boost revenue potential and validates the drug's efficacy and safety profile on an international stage. Investors will now watch for the commercial launch timeline and initial sales performance in the UK.
At the time of this announcement, KRYS was trading at $309.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1B. The 52-week trading range was $122.80 to $319.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.